Status:
RECRUITING
Zero Fluoroscopy Voltage Guided vs. Linear CTI Ablation
Lead Sponsor:
Klinikum-Fuerth
Collaborating Sponsors:
Boston Scientific Corporation
University of Trieste
Conditions:
Catheter Ablation
Atrial Flutter Typical
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Catheter ablation of the cavo-tricuspid isthmus (CTI) is the curative first-line therapy for typical atrial flutter. Currently, two approaches are used in clinical practice. In contrast to the convent...
Detailed Description
Rationale: Catheter ablation of the CTI represents the established curative first-line treatment for typical AFl. Although the acute and chronic efficacy is high, conventional ablation is still time ...
Eligibility Criteria
Inclusion
- Typical (CTI dependent) atrial flutter documented in a standard 12 lead surface ECG
- Given class I indication for curative CTI ablation according to the current guidelines
- Over 18 years old
- Given informed consent
Exclusion
- Any contraindication for CTI ablation
- Previous CTI ablation
- BCB as procedural endpoint not assessable
- CTI ablation conducted in association with further ablation procedures
- Patients with CIED (e.g. pacemaker, ICD)
- Tricuspid valve replacement
- Right atrial thrombus
- Pregnant or breastfeeding women
- Abuse of drugs or alcohol
- Age \< 18 years
- Incompliance to the treatment, e.g. necessary anticoagulation
- Expected survival less than one year
- Inability to understand the nature and rationale of the study
- Inability to take part in the follow up
Key Trial Info
Start Date :
November 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT04678258
Start Date
November 30 2020
End Date
December 31 2026
Last Update
October 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Fuerth
Fürth, Bavaria, Germany, 90766